Fig 1: Cumulative hazard curves for outcomes. Cumulative hazard curves for death stratified by SPARC levels (A) and absence or presence of sarcopenia (B). Cumulative hazard curves for relapse or death stratified by SPARC levels (C) and absence or presence of sarcopenia (D). Cumulative hazard curves for relapse stratified by SPARC levels (E) and absence or presence of sarcopenia (F).
Fig 2: Serum SPARC levels for either the absence or presence of sarcopenia. The SPARC levels are compared between the placebo group and the vitamin D group by the Mann–Whitney test.
Fig 3: BET proteins regulate expression of key drivers of fibrosis in HRMCs. HRMCs were treated with TGF-ß1 ± BETi or TGFBRi for 24 h, followed by gene expression analysis by real-time PCR (left column (A,C,E,G); n = 4 or 5). For secreted proteins (right column (B,D,F,H)), HRMCs were treated for 48 h. Cell culture media were clarified of debris by centrifugation, and the indicated proteins quantified by ELISA (n = 3). Data are presented as mean ± SD. Statistical analysis by one-way ANOVA followed by Dunnett’s Multiple Comparison Test. * p < 0.05, ** p < 0.01, *** p < 0.001, NS not significant. THBS1: thrombospondin 1 gene. FN1: fibronectin gene. POSTN: periostin gene. SPARC gene and SPARC protein: secreted protein acidic and rich in cysteine. TGF-ß1: Transforming growth factor ß1. Apabetalone: BD2-selective BET inhibitor. JQ1: pan-BET inhibitor. MZ1: PROTAC that directs BET proteins for degradation.
Supplier Page from Abcam for Human SPARC ELISA Kit